|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1638.70
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 7.05 | -0.42 | 3.51 | 13.38 | 3.40 | CEPS(Rs) | 13.72 | 5.21 | 8.66 | 15.72 | 5.71 | DPS(Rs) | 11.50 | 10.00 | 7.50 | 4.00 | 2.75 | Book NAV/Share(Rs) | 98.98 | 102.48 | 112.28 | 101.68 | 95.21 | Tax Rate(%) | 2.89 | 132.58 | 1.54 | 1.29 | -13.50 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 29.50 | 16.98 | 14.18 | 19.60 | 14.04 | EBIT Margin(%) | 10.17 | 4.42 | 7.05 | 26.46 | 10.16 | Pre Tax Margin(%) | 8.00 | 1.95 | 5.37 | 23.51 | 5.80 | PAT Margin (%) | 7.77 | -0.64 | 5.29 | 23.21 | 6.58 | Cash Profit Margin (%) | 15.12 | 7.95 | 13.06 | 27.27 | 11.04 | Performance Ratios | | | | | | ROA(%) | 4.10 | -0.23 | 2.03 | 8.36 | 2.17 | ROE(%) | 7.00 | -0.39 | 3.28 | 13.60 | 3.62 | ROCE(%) | 7.28 | 2.19 | 3.46 | 12.19 | 4.31 | Asset Turnover(x) | 0.53 | 0.37 | 0.38 | 0.36 | 0.33 | Sales/Fixed Asset(x) | 1.25 | 0.95 | 1.32 | 1.76 | 1.77 | Working Capital/Sales(x) | 2.70 | -39.08 | 5.73 | 18.76 | -5.90 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.80 | 1.05 | 0.76 | 0.57 | 0.57 | Receivable days | 95.31 | 125.78 | 146.18 | 147.72 | 151.60 | Inventory Days | 61.97 | 79.29 | 69.43 | 71.57 | 72.52 | Payable days | 175.92 | 217.66 | 220.03 | 171.17 | 234.55 | Valuation Parameters | | | | | | PER(x) | 139.51 | 0.00 | 170.21 | 26.32 | 140.81 | PCE(x) | 71.66 | 175.60 | 68.97 | 22.40 | 83.96 | Price/Book(x) | 9.93 | 8.93 | 5.32 | 3.46 | 5.03 | Yield(%) | 1.17 | 1.09 | 1.26 | 1.14 | 0.57 | EV/Net Sales(x) | 11.68 | 14.36 | 10.64 | 7.20 | 11.75 | EV/Core EBITDA(x) | 36.00 | 57.90 | 61.31 | 21.37 | 39.99 | EV/EBIT(x) | 109.82 | 322.06 | 133.70 | 24.65 | 96.07 | EV/CE(x) | 5.88 | 5.45 | 3.40 | 2.33 | 3.18 | M Cap / Sales | 11.33 | 14.08 | 10.16 | 6.74 | 11.16 | Growth Ratio | | | | | | Net Sales Growth(%) | 33.53 | 10.41 | 12.64 | 21.63 | 14.70 | Core EBITDA Growth(%) | 74.67 | 57.83 | -42.00 | 39.46 | 43.74 | EBIT Growth(%) | 218.47 | -38.12 | -69.32 | 190.47 | 88.52 | PAT Growth(%) | 1,790.89 | -111.87 | -73.77 | 293.23 | 167.18 | EPS Growth(%) | 1,791.07 | -111.87 | -73.77 | 293.23 | 167.17 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.32 | 0.20 | 0.26 | 0.26 | 0.28 | Current Ratio(x) | 1.97 | 0.96 | 1.28 | 1.07 | 0.84 | Quick Ratio(x) | 1.49 | 0.62 | 0.94 | 0.83 | 0.63 | Interest Cover(x) | 4.69 | 1.79 | 4.20 | 8.97 | 2.33 | Total Debt/Mcap(x) | 0.03 | 0.02 | 0.05 | 0.08 | 0.06 |
|
|
|
|
|
|